Skip to Main Content

ADVERTISEMENT

SCROLL TO CONTINUE WITH CONTENT

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Journal of Hepatology

EASL

Home
Editor's Choice
Articles and Issues
Collections
Manuscript
Journal Info
News and Media
Subscribe
EASL
More Periodicals

Advanced searchSave search

Please enter a term before submitting your search.

Submit
Log in
Register
Log in
- Submit
- Log in
Subscribe
Claim

Issue cover

April 2018

Volume 68Supplement 1S1-S926

The International Liver Congress 2018 Abstract Book

Issue cover

Current Issue
Articles in Press
Archive
- Archive

Select all

Please select at least one article in order to proceed.

Editorial Board

Published in issue: April 2018

i

PDF

Acknowledgements

Published in issue: April 2018

iv

PDF

Thursday, 12 April 2018

Epidemiology, predictors and outcomes of multi drug resistant bacterial infections in patients with cirrhosis across the world. Final results of the “Global study”

S. Piano,
V. Singh,
P. Caraceni,
...
A. Gadano,
S.K. Sarin,
P. Angeli

Published in issue: April 2018

S1

PDF

Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study

V. Ratziu,
A. Sanyal,
S. Francque,
...
M. Abdelmalek,
S. Friedman,
F. Tacke

Published in issue: April 2018

S1-S2

PDF

Sorafenib with versus without concurrent conventional transarterial chemoembolization (cTACE) in patients with advanced hepatocellular carcinoma (HCC): Results from a multicenter, open-label, randomized, controlled phase III STAH trial

J.-W. Park,
Y.J. Kim,
D.Y. Kim,
...
J.E. Yeon,
B.H. Kim,
J.-S. Hwang

Published in issue: April 2018

S2

PDF

Integrative molecular classification of extrahepatic cholangiocarcinoma

R. Montal,
W.Q. Leow,
C. Montironi,
...
A. Villanueva,
M. Schwartz,
J.M. Llovet

Published in issue: April 2018

S2-S3

PDF

Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection

H. Wedemeyer,
P. Bogomolov,
A. Blank,
...
J.S.Z. Wiesch,
A. Alexandrov,
S. Urban

Published in issue: April 2018

S3

PDF

Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naīve participants

T. Asselah,
S. Pol,
C. Hezode,
...
B. Haber,
R. Talwani,
L. Serfaty

Published in issue: April 2018

S3-S4

PDF

Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial

C. Corpechot,
A. Rousseau,
O. Chazouillères,
...
F.-H. Admane,
T. Simon,
R. Poupon

Published in issue: April 2018

S3-S4

PDF

Are the Globe and UK-PBC scores also effective for predicting risk in patients treated with bezafibrate in addition to ursodeoxycholic acid?: A validation study in Japan

A. Tanaka,
A. Komori,
M. Abe,
...
S. Mochida,
H. Yoshiji,
H. Takikawa

Published in issue: April 2018

S4-S5

PDF

Sub-cutaneously delivered mesenchymal stromal cells and down-regulation of activated vascular endothelium – a novel, clinically ready, therapeutic approach to treating cholestatic liver disease

V. Vigneswara,
N.-T. Luu,
M. Alfaifi,
...
S. Elliman,
G. Hirschfield,
P. Newsome

Published in issue: April 2018

S5

PDF

The gut-liver axis is essential for disease progression in the Mdr2–/– mouse model of primary sclerosing cholangitis

L. Liao,
K.M. Schneider,
M. Frissen,
...
V. Bieghs,
F.J. Cubero,
C. Trautwein

Published in issue: April 2018

S5-S6

PDF

Immunomodulatory mechanisms of the novel therapeutic bile acid 24-nor-ursodeoxycholic acid

C.I. Zhu,
N. Boucheron,
C.D. Fuchs,
...
A. Bergthaler,
W. Ellmeier,
M. Trauner

Published in issue: April 2018

S6-S7

PDF

Autoantibodies against Huntingtin-interacting protein 1-related protein are superior to conventinal autoantibodies in diagnosing autoimmune hepatitis in adults

R. Taubert,
N.T. Baerlecken,
C. Lalanne,
...
M.P. Manns,
T. Witte,
E. Jaeckel

Published in issue: April 2018

S7

PDF

Intestine-specific deletion of Abcg5/g8 leads to hepatobiliary cholesterol overload: pathophysiology of biliary lipid secretion

R. Charlotte,
B. Annika,
M. Krawczyk,
F. Lammert,
S.N. Weber

Published in issue: April 2018

S7-S8

PDF

Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis – even in patients without biochemical improvements

M. Harms,
H. Van Buuren,
W.J. Lammers,
...
G. Hirschfield,
B. Hansen,
A. Van der Meer

Published in issue: April 2018

S8

PDF

Stem cells as a new therapeutic strategy for portal hypertension and cirrhosis

A. Fernández-Iglesias,
G. Pietrosi,
M. Pampalone,
...
A. Luca,
J. Bosch,
J. Gracia-Sancho

Published in issue: April 2018

S8-S9

PDF

Targeting the nitric-oxide downstream pathway in bile-duct ligated rats to improve portal hypertension and liver fibrosis

K. Brusilovskaya,
P. Königshofer,
D. Lampach,
...
M. Trauner,
T. Reiberger,
P. Schwabl

Published in issue: April 2018

S9

PDF

Serum concentrations of Macrophage Migration Inhibitory Factor (MIF) and its soluble receptor CD74 predict transplant-free shortterm survival in patients with acute decompensation of liver cirrhosis

T. Wirtz,
N. Köse,
B. Irina,
...
A. Stallmach,
M.-L. Berres,
T. Bruns

Published in issue: April 2018

S9-S10

PDF

Oxidized albumin present in patients with decompensated cirrhosis triggers the inflammatory response in peripheral leukocytes through the p38 MAP kinase pathway

J.A. Quiles,
M. Casulleras,
K. Oettl,
...
R.E. Stauber,
V. Arroyo,
J. Clària

Published in issue: April 2018

S10

PDF

Lessons from ATTIRE feasibility study: differential inflammatory response profiles following treatment with albumin correlate with 6 months survival

N. Becares,
S. Harmala,
L. China,
...
K. Bennett,
Z. Shabir,
A. O’brien

Published in issue: April 2018

S10-S11

PDF

Acute-on-chronic liver failure is characterised by hepatocyte gasdermin D cleavage and release of the pro-inflammatory Damage Associated Molecular Pattern (DAMP) IL-α

U. Soffientini,
N. Beaton,
A. Habtesion,
...
R. Moreau,
R. Jalan,
G. Mehta

Published in issue: April 2018

S11

PDF

Gut microbiome is profoundly altered in acute-on-chronic liver failure as evaluated by quantitative metagenomics. Relationship with liver cirrhosis severity

C. Sole,
M. Llopis,
E. Solà,
...
J. Doré,
D. Ehrlich,
P. Ginès

Published in issue: April 2018

S11-S12

PDF

Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

J.S. Bajaj,
R. Idilman,
L. Mabudian,
...
R. Brown,
M. Sikaroodi,
P. Gillevet

Published in issue: April 2018

S12-S13

PDF

Personalized T cell therapy against HBV-related hepatocellularcarcinoma

A. Tan,
T. Krishnamoorthy,
N. Yang,
...
E. Guccione,
W.C. Chow,
A. Bertoletti

Published in issue: April 2018

S12-S13

PDF

Role of 99mTc-Macroaggregated Albumin SPECT/CT based dosimetry in predicting survival and tumor response of patients with locally advanced and inoperable hepatocellular carcinoma (HCC) treated by selective intra-arterial radiation therapy (SIRT) with yttrium-90 resin microspheres, a cohort from SARAH study

A.-L. Hermann,
A. Dieudonné,
R. Maxime,
...
L. Rachida,
V. Vilgrain,
S.T. Group

Published in issue: April 2018

S13

PDF

Pattern of progression determines post-progression survival in patients with hepatocellular carcinoma treated with Radioembolization

C. Jordan,
M. de la Torre,
A.C. Gardini,
...
J.I. Herrero,
J. Quiroga,
B. Sangro

Published in issue: April 2018

S13

PDF

Lower compliance to prior HCC surveillance and liver function impairment explain the apparent higher HCC incidence under direct antivirals in HCV compensated cirrhotic patients: the French multicenter prospective ANRS CO12 CirVir cohort experience

P. Nahon,
L. Richard,
B. Valerie,
...
D. Larrey,
R. Francoise,
E. Audureau

Published in issue: April 2018

S14

PDF

Post-treatment liver stiffness measurement is not useful to predict hepatocellular carcinoma in HCV patients who achieve SVR

S. Shili,
S. Giovanna,
J. Foucher,
...
P.-H. Bernard,
V. De Ledinghen,
C. Hezode

Published in issue: April 2018

S14

PDF

Efficacy and safety of REGORAFENIB in real life in the treatment of hepatocellular carcinoma. Multicenter experience

M. Fraile,
M.T. Ferrer,
A.M. Matilla,
...
D.E.M. Arraez,
M.J.B. Rodriguez,
M. Varela

Published in issue: April 2018

S15

PDF

Pathological characteristics and early post-hepatic-resection outcome of patients with hepatocellular carcinoma occurred after hepatitis C treatment with new direct-acting antivirals: a multicenter cohort study

A. Vitale,
F.P. Russo,
C. Sposito,
...
D. Ghinolfi,
D. Nicolini,
F. Trevisani

Published in issue: April 2018

S15

PDF

Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study

T. Meyer,
I. Melero,
T. Yau,
...
T. Crocenzi,
A. El-Khoureiry,
B. Sangro

Published in issue: April 2018

S16

PDF

Combinatorial RNAi/vaccination therapy for chronic hepatitis B achieves long-term functional cure in preclinical mouse model

T. Michler,
A. Kosinska,
T. Bunse,
...
S. Milstein,
L. Sepp-Lorenzino,
U. Protzer

Published in issue: April 2018

S16

PDF

Novel and potent HBV capsid modulator reduces HBeAg and cccDNA in core site directed T109I mutant in HepNTCP cells

L. Bassit,
B. Cox,
S.K. Ono,
...
J. Yoon,
F. Amblard,
R.F. Schinazi

Published in issue: April 2018

S16-S17

PDF

Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer

N. Mani,
A.H.L. Li,
A. Ardzinski,
...
X. Teng,
M. Wong,
M.J. Sofia

Published in issue: April 2018

S17

PDF

Combination treatment of a TLR7 agonist RO7020531and a capsid assembly modulator RO7049389 achieved sustainable viral loadsuppression and HBsAg loss in an AAV-HBV mouse model

L. Dai,
Y. Yu,
L. Gu,
...
W. Zhu,
J. Young,
L. Gao

Published in issue: April 2018

S17-S18

PDF

Durable inhibition of hepatitis B virus replication and antigenemia using a subcutaneously administered siRNA agent in preclinical models

A.C.H. Lee,
J. Heyes,
X. Ye,
...
N.M. Snead,
A. Martin,
M.J. Sofia

Published in issue: April 2018

S18

PDF

Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection

C. Wooddell,
R. Zhu,
H. Hamilton,
...
M. Seefeld,
Z. Li,
B. Given

Published in issue: April 2018

S18-S19

PDF

T cells grafted with HBV-specific T-cell receptors of high functional avidity achieve functional cure of HBV infection in humanized mice

K. Wisskirchen,
J. Kah,
A. Malo,
...
A. Krackhardt,
M. Dandri-Petersen,
U. Protzer

Published in issue: April 2018

S19

PDF

Discovery of a novel core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model

M. Vaine,
S. Clugston,
J. Kass,
...
Y.-L. Qiu,
Y.S. Or,
K. Lin

Published in issue: April 2018

S19

PDF

Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV-TARGET Cohort

E. Verna,
G. Morelli,
N. Terrault,
...
D.R. Nelson,
M.W. Fried,
R. Reddy

Published in issue: April 2018

S19-S20

PDF

8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort

A. Boyle,
F. Marra,
E. Peters,
...
H. Cairns,
S. Datta,
S. Barclay

Published in issue: April 2018

S20

PDF

Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis

M.B. Ferret,
J. Pineda,
J.L.C. Panero,
...
S. Lens,
M. Casado,
R. Esteban

Published in issue: April 2018

S20-S21

PDF

Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST) – does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R)

S. Christensen,
P. Buggisch,
S. Mauss,
...
J. Reimer,
H. Wedemeyer,
D.H. C-Register

Published in issue: April 2018

S21-S22

PDF

Estimated glomerular filtration rate variations and direct acting antivirals treatment for chronic hepatitis C: a retrospective longitudinal study

V. Mallet,
L. Parlati,
O. Dorval,
...
H. Fontaine,
P. Sogni,
S. Pol

Published in issue: April 2018

S22

PDF

Spontaneous clearance of HCV RNA after documented relapse following DAA-therapy: A case-control study

H. Kuriry,
L. Krassenburg,
M. Kuczynski,
...
B. Hansen,
H. Janssen,
J. Feld

Published in issue: April 2018

S22-S23

PDF

NS5A resistance patterns and treatment outcomes in DAA-naive genotype 1a chronic hepatitis C patients with and without baseline resistance-associated substitutions

J. Dietz,
J. Vermehren,
S. Susser,
...
C. Berg,
S. Zeuzem,
C. Sarrazin

Published in issue: April 2018

S23

PDF

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

D. Wyles,
O. Weiland,
B. Yao,
...
T. Pilot-Matias,
L.R. Jr,
R. Trinh

Published in issue: April 2018

S23-S24

PDF

Frequencyand outcomes of liver transplantation for nonalcoholic steatohepatitis in Europe

D. Haldar,
B. Kern,
J. Hodson,
...
P. Muiesan,
S. Schneeberger,
P. Newsome

Published in issue: April 2018

S24-S25

PDF

Liver transplantation in patients with multiple organ failures is feasible with good outcomes

P.J. Thuluvath,
A. Thuluvath,
Y. Savva

Published in issue: April 2018

S25

PDF

Results per page:50

1
2
3
4
5
6
7
8
9

Login to your account

Email/Username

Password

Forgot password?

Remember me

Don’t have an account?

Create a Free Account

If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

Email*

If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password

The content on this site is intended for healthcare professionals.

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.

Copyright © 2023 Elsevier Inc. except certain content provided by third parties.

Privacy Policy
Terms and Conditions
Accessibility
Help & Contact

RELX